RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via Upregulating PUMA by Zhang, Kejun et al.
Int. J. Mol. Sci. 2011, 12, 385-400; doi:10.3390/ijms12010385 
 





RNA Interference Targeting Slug Increases 
Cholangiocarcinoma Cell Sensitivity to Cisplatin via 
Upregulating PUMA 
Kejun Zhang 
1,†, Dong Chen 
1,†,*, Xingang Wang 
1, Shaoyan Zhang 
2, Jigang Wang 
3, Yuan Gao 
4 
and Bomin Yan 
1 
1  General Surgery of the Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shan 
Dong Province 266003, China; E-Mails: wlsdermyy@163.com (K.Z); 
wangxingang77521@126.com (X.W.); yanbm818@yahoo.com.cn (B.Y.) 
2  Laboratory of the Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shan Dong 
Province 266003, China; E-Mail: zlfzyj2009@163.com 
3  Pathology, The Affiliated Hospital of Medical College, QingDao University, Qingdao, Shan Dong 
Province 266003, China; E-Mail: Love5028@sohu.com   
4  Molecular Biology, The Affiliated Hospital of Medical College, QingDao University, Qingdao, 
Shan Dong Province 266003, China; E-Mail: isgs@rocketmail.com 
†  These authors contributed equally to this work. 
*  Author to whom correspondence should be addressed; E-Mail: Chendong.sdqd@yahoo.com.cn.
 
Received: 9 December 2010; in revised form: 6 January 2011 / Accepted: 7 January 2011 /  
Published: 14 January 2011 
 
Abstract: Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated 
modulator of apoptosis) and it has recently been demonstrated that Slug plays an important 
role in controlling apoptosis. In this study, we examined whether Slug’s ability to silence 
expression suppresses the growth of cholangiocarcinoma cells and/or sensitizes 
cholangiocarcinoma cells to chemotherapeutic agents through induction of apoptosis. We 
targeted the Slug gene using siRNA (Slug siRNA) via full Slug cDNA plasmid (Slug cDNA) 
transfection of cholangiocarcinoma cells. Slug siRNA, cisplatin, or Slug siRNA in 
combination with cisplatin, were used to treat cholangiocarcinoma cells in vitro. Western 
blot was used to detect the expression of Slug, PUMA, and E-cadherin protein. TUNEL, 
Annexin V Staining, and cell cycle analysis were used to detect apoptosis. A nude mice 
subcutaneous xenograft model of QBC939 cells was used to assess the effect of Slug 
silencing and/or cisplatin on tumor growth. Immunohistochemical staining was used to 
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analyze the expression of Slug and PUMA. TUNEL was used to detect apoptosis in vivo. 
The results showed that PUMA and E-cadherin expression in cholangiocarcinoma cells is 
Slug dependent. We demonstrated that Slug silencing and cisplatin both promote apoptosis 
by upregulation of PUMA, not by upregulation of E-cadherin. Slug silencing significantly 
sensitized cholangiocarcinoma cells to cisplatin through upregulation of PUMA. Finally, we 
showed that Slug silencing suppressed the growth of QBC939 xenograft tumors and 
sensitized the tumor cells to cisplatin through PUMA upregulation and induction of 
apoptosis. Our findings indicate that Slug is an important modulator of the therapeutic 
response of cholangiocarcinoma cells and is potentially useful as a sensitizer in 
cholangiocarcinoma therapy. One of the mechanisms is the regulation of PUMA by Slug.  
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1. Introduction 
Despite the aggressive multidisciplinary cancer therapies that have been used clinically, the 
prognosis of cholangiocarcinoma patients is extremely poor due to the low resection rate and the 
tolerance of the cancer to chemotherapy and radiotherapy [1,2]. For this reason, it is important to find 
new methods to enhance the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. Gene 
therapy for cholangiocarcinoma is potentially a promising approach. The identification of molecules 
involved in the regulation and induction of apoptosis in cholangiocarcinoma has recently been reported 
and has generated new biological treatments aimed at enhancing chemotherapy-induced cell 
apoptosis [3–5].   
The human Slug gene belongs to the highly conserved Slug/Snail family of transcription repressors, 
master regulators of neural crest cell specification and melanocyte migration during development in 
vertebrates [6–10]. Previous studies have demonstrated that the overexpression of Slug can be found in 
many kinds of cancer [11–14]. Moreover, Slug activates multiple signal intermediates, such as 
E-cadherin, which are key factors that influence the events of tumor invasion and metastasis [15,16]. 
In addition, Slug promotes survival and hinders cell death by directly suppressing PUMA, a key 
BH3-only antagonist of the anti-apoptotic Bcl-2 protein [17,18]. A previous study has demonstrated 
that PUMA is an important modulator of the therapeutic response of lung cancer cells and is 
potentially useful as a sensitizer in lung cancer therapy [19]. There have been a few studies devoted to 
the role of Slug in the chemoresistance of cancer cells to anti-cancer agents. A recent report indicated 
the possibility that Slug enhances chemoresistance of malignant mesothelioma cells to doxorubicin, 
paclitaxel, and vincristine [20]. It has been reported by Kurrey NK that Slug plays a critical role in the 
ability of a cancer cell to acquire stem cell characteristics to resist radiotherapy or 
chemotherapy-mediated cellular stress [21]. Roberta et al. [22] has reported that Slug down-regulation 
facilitates the apoptosis induced by proapoptotic drugs in neuroblastoma cells and decreases their 
invasion capability in vitro and in vivo, and that Slug silencing enhances the efficacy of cisplatin and 
fotemustine in the treatment of melanoma [23].   Int. J. Mol. Sci. 2011, 12                 
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However, to the best of our knowledge, the roles and possible mechanisms of Slug in the 
chemoresistance of cholangiocarcinoma cells to cisplatin have not been previously reported. The aim 
of this study is to investigate and define the ability and mechanism of Slug silencing to increase the 
susceptibility of cholangiocarcinoma cell lines to the currently used cytotoxic drug cisplatin.   
2. Materials and Methods 
2.1. Cell Culture 
The human cholangiocarcinoma cell lines QBC939, RBE, ICC-9810 and FRH 0201 were purchased 
from ATCC and conserved in the central laboratory of the first affiliated Hospital of Suzhou 
University, China. Cells were grown in HAMs F12 medium supplemented with 10% fetal bovine 
serum at 37 °C in a 5% CO2 humidified atmosphere.   
2.2. siRNA and cDNA Transfection 
The siRNA targeting Slug (Slug siRNA, sc-38393) and mock siRNA (mock, sc-37007), the siRNA 
targeting PUMA (PUMA siRNA, sc-37153) and mock siRNA (mock, sc-33007) was obtained from 
Santa Cruz Biotechnology. Mock siRNA is a non-targeting 0–25nt siRNA designed to serve as a 
negative control. In a six well tissue culture plate, we seeded 2 × 10
5 cholangiocarcinoma cells per 
well in 2 mL antibiotic-free normal growth medium supplemented with FBS. We then incubated the 
QBC939 cells at 37 °C in a CO2 incubator until the cells were 60–80% confluent for 24 hours. The 
following solutions were prepared: Solution A: For each transfection, 2–8 µL of siRNA duplex 
(i.e., 0.25–1 µg siRNA) was diluted into 100 µL siRNA transfection medium: sc-36868 (Santa Cruz). 
Solution B: For each transfection, 6 µL of siRNA transfection reagent: sc-29528 (Santa Cruz, CA, 
USA) was diluted into 100 µL siRNA transfection medium: sc-36868(Santa Cruz, CA, USA). The 
siRNA duplex solution was then added (Solution A) directly to the diluted transfection reagent 
(Solution B) using a pipette and mixed gently by pipetting the solution up and down, then incubated 
for 30 minutes at room temperature. We then washed the cells once with 2 mL of siRNA transfection 
medium: sc-36868. For each transfection, we added 0.8 mL siRNA transfection medium to each tube 
containing the siRNA transfection reagent mixture (Solution A + Solution B) and then mixed gently 
and overlayed the mixture onto the washed cells. The cells were then incubated for 6 hours at 37 °C in 
a CO2 incubator. A volume of 1 mL of normal growth medium containing 2 times the normal serum 
and antibiotics concentration (2 × normal growth medium) was then added without removing the 
transfection mixture, and the cells were subsequently incubated for an additional 24 hours, at which 
time the medium was aspirated and we proceeded immediately to the next step. We performed Western 
blot on the cells 0–72 h after the addition of fresh medium in the step above. Mock siRNA containing a 
scrambled sequence that would not lead to the specific degradation of cellular Slug mRNA was 
transfected as above. The plasmid vector with the full coding region of human Slug (pcDNA3-Slug 
cDNA, Slug cDNA in brief) and the mock vector (pcDNA3-EGFP, mock cDNA in brief) were created 
in our laboratory (16). Transfection of Slug cDNA was performed using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. In brief, 1 μg Slug 
cDNA was mixed with 3 μg Lipofectamine 2000 at a final concentration of 2 μg Slug cDNA/mL Int. J. Mol. Sci. 2011, 12                 
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dissolved in OPTI-MEM I (Invitrogen), and the resulting complex was added to the cells and the FRH 
0201cells were incubated with the complex for 4 h. FRH 0201 cells were washed with PBS and further 
incubated with the culture medium for specified time periods ranging from 0–72 h. Stably expressed 
Slug siRNA (mock) clones were selected by using medium containing G418 (500 µg/mL) for 28 days. 
Cells were routinely maintained in selection media containing 200 µg/mL of G418-sulfate to avoid 
overgrowth of nontransfected cells.   
2.3. Western Blot 
We collected approximately 2.0 × 10
7 cells (at different conditions) by low-speed centrifugation 
(e.g., 200 × g) at room temperature for 5 minutes and carefully removed the culture medium. Next, we 
washed the pellet with PBS at room temperature, and again collected cells by low-speed centrifugation 
and carefully removed the supernatant. We added 1.0 mL of ice cold RIPA buffer with freshly added 
Protease Inhibitors and gently resuspended the cells in RIPA buffer with a pipette and incubated the 
cells on ice for 30 minutes. We then further disrupted and homogenized the cells by hydrodynamic 
shearing (21-gauge needle), dounce homogenization (Optional: Add 10 µL of 10 mg/mL PMSF stock), 
and then incubated the cells for 30 minutes on ice. Next, samples were transfered to microcentrifuge 
tube(s) and centrifuged at 10,000 × g for 10 minutes at 4 °C. The supernatant fluid represented the total 
cell lysate and the supernatant was transferred to a new microfuge tube and represented the whole cell 
lysate. Total protein was measured in the extract by the Bradford assay. Primary antibodies were as 
follows: Anti-Slug (1:200 dilution), Anti–PUMA (1:400 dilution), and Anti-ß-actin (1:500 dilution), all 
from Santa Cruz Biotechnology. The membrane was probed using horseradish peroxidase–conjugated 
immunoglobulins (DAKO) as described previously (24). Western blot images were captured using an 
Epi Chemi II Darkroom and Sensicam imager with Labworks 4 software (UVP).   
2.4. Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling Assay 
Cells in different groups were cultured on chamber slides for 24 h. Apoptosis of the cells was 
evaluated on the basis of the TUNEL assay using the Dead End Fluorometric TUNEL System 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. All assays were 
performed in quadruplicate.   
2.5. Cell Cycle Analysis   
The cells in different groups and time points were washed twice with PBS and fixed with 70% 
ethanol/PBS. They were then treated with 0. 5 mg/mL RNase (Sigma) in PBS with 0.1% saponin, and 
incubated at 37 °C for 30 min before staining with 20 μg/mL PI for 30 min at 4 °C. The cells (1 × 10
6) 
were then analyzed for DNA content using a FACSCalibur flow cytometer equipped with CellQuest 
software (Becton Dickinson Immunocytometry Systems).   
2.6. Annexin V Staining 
The Annexin V assays were performed according to the manufacture’s protocol (PharMingen). 
Briefly, the cultured cells were collected, washed with binding buffer, and incubated in 200 μL of a Int. J. Mol. Sci. 2011, 12                 
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binding buffer containing 5 μL of Annexin-V-FITC. The nuclei were counterstained with PI. The 
percentage of apoptotic cells was determined using a FACSCalibur flow cytometer (Becton Dickinson 
Immunocytometry Systems, San Jose, CA, USA).   
2.7. Xenograft Tumors   
Immunodeficient female mice, 4 to 6 weeks old, were purchased from the Shanghai Animal Center. 
Autoclaved cages containing food and water were changed once a week. Mouse body weight was 
measured every 3 to 4 days. On the day of tumor cell inoculation, tumor cells at 70% to 80% 
confluence were trypsinized and resuspended in fetal bovine serum-free culture medium. Xenograft 
tumors were established by subcutaneous injection of 5 × 10
6 BQC939 cells (stable transfected with 
Slug siRNA or mock) into the flanks of 4 to 6 week old female Nude mice (n = 6 per group). In the 
combination model, cisplatin (3 mg/kg/d) was injected intraperitoneally into the mice on days 6–8. 
Mock transfected BQC939 cells were injected into separate tumors in the same animals. Tumor growth 
was monitored every other day with calipers for 28 days to calculate tumor volume according to the 
formula [length × width
2]/2.  
2.8. Immunohistochemistry in Xenograft Tumors   
Tumor samples fixed in 10% neutral buffered formalin were embedded in paraffin using automatic 
embedding equipment, after which 5 μm sections were prepared. Immunohistochemical analyses for 
Slug and PUMA were performed on paraffin-embedded sections of mice treated with Slug siRNA or 
mock siRNA according to
 the manufacturer’s instruction.   
2.9. TUNEL Staining in Vivo 
Paraffin-embedded tumor sections were used to identify apoptotic cells by terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining following the 
vendor’s protocol. A section was incubated with nuclease to generate DNA strand breaks for positive 
control. Endogenous peroxidase activity was quenched by 5% H2O2 (in methanol, v/v) and sections 
were incubated with terminal deoxynucleotidyl transferase labeling buffer followed with terminal 
deoxynucleotidyl transferase enzyme and biotinylated nucleotides (for negative control, labeling buffer 
was used instead of terminal deoxynucleotidyl transferase enzyme). Sections were incubated with 
streptavidin-conjugated horseradish peroxidase followed with 3,3′-diaminobenzidine solution (Sigma) 
and counterstained with diluted hematoxylin. Apoptosis was evaluated by counting the 
TUNEL-positive cells together with the total number of cells at 5 randomly selected fields at ×400 
magnification in each tumor; the data are presented as percent TUNEL-positive cells.   
2.10. Statistics   
All statistical analyses were performed using SPSS13.0 software. The results were presented as 
mean ± SD of three separate assays. Differences between various groups were assessed using the 
ANOVA or Dunnett t-test. A P value of <0.05 was considered to indicate statistical significance.   Int. J. Mol. Sci. 2011, 12                 
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3. Results   
3.1. Slug Regulates PUMA and E-Cadherin Expression in Cholangiocarcinoma Cells 
Slug expression was examined in a panel of four cholangiocarcinoma cell lines QBC939, RBE, 
ICC-9810, and FRH0201 by Western blot. The results indicated that the cell line FRH 0201 exhibited 
the lowest expression level of Slug and that QBC939 exhibited the highest expression level of Slug 
(Figure 1A). In this regard, the cell lines FRH 0201 and QBC939 were chosen for the studies.   
The cell line FRH0201 was transiently transfected with either full length human Slug cDNA vector 
or the mock vector for 48 h to increase the expression of Slug. The cell line QBC939 was transiently 
transfected with Slug siRNA for 48 h to knock down Slug. In Slug siRNA-transfected QBC939 cells, 
Slug expression was barely detectable compared with parental cells (Figure 1B), whereas Slug 
cDNA-transfected FRH 0201 cells expressed a higher level of Slug compared with parental cells 
(Figure 1C).   
Figure 1. Slug regulation-induced processing of Slug and PUMA. (A)  The protein 
fractions of Slug in QBC939, RBE, ICC-9810, and FRH 0201 cells were subjected to 
Western blot analysis. FRH 0201 exhibited the lowest expression level of Slug and 
QBC939 exhibited the highest expression level of Slug. (B) The protein fractions of Slug, 
E-cadherin, and PUMA in QBC939 cells after transfection with Slug siRNA for 48 h were 
subjected to Western blot analysis. Slug expression was barely detectable compared with 
parental cells (**P < 0.01), and a remarkble upregulation of E-cadherin and PUMA protein 
was shown compared with parental cells (*P < 0.05). (C) The protein fractions of Slug, 
E-cadherin, and PUMA in the FRH 0201 cell line after transfection with Slug cDNA for 
48 h were subjected to Western blot analysis. Remarkable upregulation of Slug protein was 
shown compared with parental cells (**P  < 0.01), and remarkable downregulation of 
PUMA and E-cadherin proteins was shown compared with parental cells (*P < 0.05).   
 Int. J. Mol. Sci. 2011, 12                 
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Slug is a suppressor of PUMA transcription (18). To evaluate whether Slug plays a role in the 
regulation of PUMA in cholangiocarcinoma cell lines, we analyzed the expression of PUMA in Slug 
siRNA-transfected QBC939 cells and Slug cDNA-transfected FRH 0201 cells by Western blot. In Slug 
siRNA-transfected QBC939 cells, PUMA was up-regulated compared with parental cells (Figure 1B). 
By contrast, in Slug cDNA-transfected FRH 0201, no PUMA expression was seen compared with 
parental cells (Figure 1C).   
It has been recently reported that the Slug transcription factor directly represses E-cadherin 
expression in many epithelial cancers associated with epithelial-mesenchymal transitions. The reverse 
correlation of Slug and E-cadherin expression has been noted in many malignant cells. We found in 
our study that Slug siRNA-transfected QBC939 cells showed a remarkble upregulation of E-cadherin 
protein compared with parental cells (Figure 1B) and that a remarkable downregulation of E-cadherin 
protein was shown in Slug cDNA-transfected FRH 0201 cells compared with parental cells 
(Figure 1C). These observations provided direct evidence that Slug regulated E-cadherin and PUMA 
expression in human cholangiocarcinoma cells. 
3.2. Slug Inhibition by siRNA Promotes Apoptosis in Cholangiocarcinoma Cells 
It has been previously demonstrated that Slug is involved in the control of apoptosis [17]. We next 
hypothesized that Slug silencing may have proapoptotic effects on cholangiocarcinoma cells. To 
investigate this, cell apoptosis was detected in QBC93 cells transiently transfected with Slug siRNA or 
mock for 48h by TUNEL analysis. It showed that the apoptosis rate in Slug siRNA-transfected 
QBC939 cells was significantly increased compared with the control or mock-transfected QBC939 
cells (*P < 0.05, Figure 2).   
Figure 2. TUNEL staining was performed for QBC939 cells transiently transfected with 
Slug siRNA or mock transfected for 48hs. Green nuclear staining indicates apoptotic cells. 
The percentage of TUNEL-positive cells was quantified. Columns and bars represent the 
mean and standard deviation of three independent determinations, respectively. Significant 
differences between the controls (mock) and the Slug siRNA groups are indicated by 
*P < 0.05.   
 
To explore whether Slug inhibition by RNA interference promotes apoptosis by upregulating 
PUMA, and not by upregulating E-cadherin, we examined the effects of Z-DEVD-CHO, a caspase-3 
inhibitor, on the internucleosomal degradation of DNA. It showed that the treatment of QBC939 cells 
with the inhibitor combined with transfection of Slug siRNA for 48 h resulted in significantly 
decreased cell apoptosis in contrast to only Slug siRNA treated groups (Figure 2, *P < 0.05). Int. J. Mol. Sci. 2011, 12                 
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3.3. Cisplatin promotes Cholangiocarcinoma Cells Apoptosis in Vitro 
This study demonstrated that cisplatin induced apoptosis in human cholangiocarcinoma cell lines 
QBC939 and FRH0201 in a concentration- and time-dependent manner. As shown in Figure 3A and 
Figure B, treating the cholangiocarcinoma cells with 0.1 μg/mL cisplatin for 72 h caused only a slight 
increase in the proportion of apoptotic cells in the two cell lines. However, increasing the cisplatin 
concentration (20 μg/mL) for 72 h resulted in a sharp increase in the proportion of apoptotic cells, 
suggesting that cell death occurred in a dose-dependent manner (compared to control, *P  <  0.05, 
**P < 0.01, ***P < 0.001).   
When the cholangiocarcinoma cells were exposed to 20 μg/mL cisplatin, the proportion of 
apoptotic cells increased in a time-dependent manner. Almost 70% (FRH 0201), over 40% (QBC939) 
of the other cell population underwent apoptosis after 72 h, compared with ≤5% of the control 
(BPS-treated) cells (Figure 3A,B).   
Similar results were obtained when the apoptosis was monitored by cell cycle analysis. Exposure to 
20  μg/mL cisplatin for 12–24 h had no remarkable effect on the cell cycle distribution of the 
cholangiocarcinoma cells. However, the cisplatin treatment for 48–72 h resulted in a progressive 
increase in the sub-G1 cell fraction. (Figure 3C, D) (contrast to control, *P < 0.05, **P < 0.01, 
***P < 0.001). 
Figure 3. Cisplatin-induced apoptosis in QBC939 and FRH 0201 cells. A, C, QBC939 and 
FRH0201 cells (1 × 10
6/mL) were exposed to the designated concentrations of cisplatin for 
the indicated times, after which time the percentage of apoptotic cells was determined by 
flow cytometric analysis, as described in “Materials and Methods”. The data are expressed 
as a mean value of the percentage of apoptotic cells from three independent experiments 
performed in duplicate (*P < 0.05, **P < 0.01, ***P < 0.001). B, D, At the indicated time 
points after treatment with 20 µg/mL cisplatin, the cells were harvested and fixed in 70% 
ethanol. After staining with PI, the apoptotic DNA content was analyzed by flow cytometry. 
The number of apoptotic cells in the sub-G1 fraction is expressed as a percentage of the 
total number of cells (*P < 0.05, **P < 0.01, ***P < 0.001).   
 Int. J. Mol. Sci. 2011, 12                 
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3.4. Cisplatin Cytotoxicity Is Associated with PUMA Induction 
Figure 4. Induction of apoptosis by cisplatin is independent of PUMA mechanism. (A, B) 
The QBC939 and FRH 0201 cells were exposed to various cisplatin concentrations for 
72 h. The PUMA and E-cadherin protein expression levels in the cell lysate were examined 
by Western blot analysis using anti-PUMA (E-cadherin) antibody, and the antibodies 
against ß-actin which served as an internal control. (C, D) The QBC939 and FRH 0201 
cells were exposed to 20 µg/mL cisplatin for the indicated times. The PUMA and 
E-cadherin protein expression level was measured by Western blot. (E, F) QBC939 and 
FRH0201 cells (1 × 10
6/mL) were exposed to 20 µg/mL cisplatin combined with PUMA 
siRNA for 72 h, PUMA protein expression level was measured by Western blot. (G, H) 
QBC939 and FRH0201 cells (1 × 10
6/mL) were exposed to 20 µg/mL cisplatin combined 
with PUMA siRNA for 72 h, after which time the percentage of apoptotic cells was 
determined by flow cytometric analysis, as described in “Materials and Methods”. 
Cisplatin combined with PUMA siRNA did not induce obvious apoptosis in QBC939 and 
FRH 0201 cells (
*P < 0.01).   
 Int. J. Mol. Sci. 2011, 12                 
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The effects of cisplatin on the intracellular level of PUMA were analyzed to additionally examine 
the relationship between cell death and PUMA in the QBC939 and FRH 0201 cholangiocarcinoma 
cells. The cells were treated with various cisplatin concentrations for 72 h, or the cells were treated 
with 20 µg/mL cisplatin concentrations for various lengths of time. The PUMA and E-cadherin 
extracted from the cells were subjected to Western blot analysis. A representative result of QBC939 
and FRH 0201 is shown in Figure 4A–D. The amount of PUMA was increased in a 
concentration-dependent and time-dependent manner, reaching a maximum level at 20 µg/mL of 
cisplatin or 72 h treatment. 
The results demonstrated that cisplatin did not obviously promote or reduce E-cadherin expression 
(Figure 4A–D). These observations provided direct evidence that cisplatin-induced apoptosis was not 
E-cadherin- dependent.   
To determine whether the induction of cell death in cisplatin-treated cholangiocarcinoma cells was 
due, in part, to regulation of PUMA expression, QBC939 and FRH 0201 cells were exposed to a 
cisplatin concentration of 20 µg/mL for 6 h, after which time the cisplatin-treated cells were 
transfected PUMA siRNA for 72 h to knock down PUMA. This study demonstrated that induction of 
PUMA was not shown in any of the PUMA siRNA treated sample populations (Figure 4E,F). Cisplatin 
combined with PUMA siRNA did not induce obvious apoptosis in QBC939 and FRH 0201 cells 
(Figure 4G,H, *P < 0.01). By contrast, mock-transfected cells exhibited PUMA levels or an apoptosis 
level similar to that found in cells treated only with cisplatin (Figure 4G,H). 
3.5. Slug Silencing and Cisplatin Treatment Act in Concert to Induce Apoptosis in 
Cholangiocarcinoma Cells   
Figure 5. TUNEL staining was performed to assess the potential cooperation of Slug 
silencing and cisplatin treatment in inducing apoptosis in QBC939 cells. Green nuclear 
staining indicates apoptotic cells. The percentage of TUNEL-positive cells was quantified. 
Columns and bars represent mean and standard deviation of three independent 
determinations, respectively. Significant differences between the controls (mock) and the 
Slug siRNA groups are indicated by *P < 0.05, **P < 0.01.   
 
 
Given the activity of Slug in cell survival through regulation of proapoptotic factor PUMA, and the 
fact that cisplatin promotes apoptosis by upregulating PUMA, we assessed the apoptosis susceptibility 
of Slug siRNA-transfected QBC939 cells in the presence of 5 µg/mL cisplatin for 48 h. At the end of Int. J. Mol. Sci. 2011, 12                 
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each treatment, cells were fixed and stained for TUNEL analysis. siRNA-transfected QBC939 cells 
combined with 5 µg/mL cisplatin showed a significantly increased apoptosis rate compared with 
siRNA-transfection only or cisplatin treatment alone (*P < 0.05, **P < 0.01) (Figure 5). 
3.6. Slug Silencing Suppresses Cholangiocarcinoma Tumor Growth and Sensitizes 
Cholangiocarcinoma Xenografts to Cisplatin in Vivo 
To determine whether  Slug silencing confers antitumor activity in vivo, established 6 × 10
6 
QBC939 cells (stable transfection with Slug siRNA or mock siRNA) were injected into the flanks of 4 
to 6 week old female Nude mice (n = 6 per group). Mock siRNA had no effect on tumor growth 
compared to the control alone, with tumors doubling in volume in 28 days compared to Slug siRNA 
treatment groups (**P < 0.01; Figure 6A).   
Furthermore, we analyzed the tumor sections from control, mock siRNA, and Slug siRNA groups 
for Slug and PUMA using immunohistochemistry. We observed significant expression levels of Slug in 
control and mock-treated tumor sections (Figure 6B). However, expression levels were drastically 
reduced in the tumor sections of mice treated with Slug siRNA. Furthermore, we observed drastically 
increased PUMA in Slug siRNA tumor sections (Figure 6B).   
Figure 6. Slug silencing sensitizes cholangiocarcinoma xenograft tumors to cisplatin. A, 
growth bar of QBC939 tumors (n = 6 per group) subjected to Slug siRNA, mock, and PBS 
and/or combined with cisplatin treatment for 28 days. B, Immunohistochemistry analysis 
for Slug and PUMA in different groups. C, TUNEL-positive cells in three groups were 
detected in the control, cisplatin, or Slug siRNA plus cisplatin treatments. Columns and 
bars represent the mean of three independent determinations and S.D., respectively. 
*P < 0.05, **P < 0.01, ***P < 0.01.   
 
Analyzing tissue sections from tumors revealed that Slug siRNA, but not mock, significantly 
increased apoptosis in the tumors as assessed by TUNEL staining (Figure 6C). These data show that 
Slug silencing effectively inhibits the growth of Cholangiocarcinoma tumors through apoptosis induction.   
Slug silencing was found to promote apoptosis by cisplatin in vitro. We wanted to determine 
whether such effects can be obtained in the QBC939 xenograft tumor model. To investigate the Int. J. Mol. Sci. 2011, 12                 
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potential additive or synergistic effects, we used cisplatin (3 mg/kg/d for 4 days) in these experiments. 
Cisplatin treatment alone resulted in 20% growth inhibition compared with mock or PBS control, 
respectively (*P < 0.05, Figure 6A). In contrast, Slug siRNA combined with cisplatin resulted in >60% 
growth suppression (***P < 0.001, Figure 6A), indicating synergism. Analysis of tumor sections 
revealed that the Slug siRNA and cisplatin combination resulted in a significant increase in apoptosis 
compared with Slug siRNA or cisplatin alone (Figure 6C). These results suggest that Slug silencing 
enhances the therapeutic response of QBC939 tumors to cisplatin through apoptosis induction.   
4. Discussion 
Resistance of cholangiocarcinoma to chemotherapy is a major problem in cancer treatment [27–29]. 
Currently, it is generally acknowledged that chemotherapeutic agents exert their cytotoxic effects 
through the activation of apoptosis and promotion of apoptosis can increase the chemosensitivity of 
cancer cells [30,31]. For this reason, inhibited expression of some specific genes that inhibit apoptotic 
cell death can cause malignant cells to be relatively sensitive to the cytotoxic effect of 
chemotherapeutic agents.   
The appearance of novel strategies for cancer treatment is based on the selective downregulation of 
specific targets involved in neoplastic progression. Slug seems to be a relevant target for such 
therapeutic intervention. Slug is detectable in many types of cancer, and its presence has been 
associated with poor prognosis in many malignant tumors [32–35]. Not only is Slug an inducer of 
epithelial-mesenchymal transition (EMT) and cell movement, it is also considered to be a factor 
favoring cell survival [16]. Previous studies have demonstrated that Slug overexpression exhibits a 
radioprotective function in TK6 cells demonstrating that it has potential as a candidate for gene 
therapeutic radioprotection of normal tissues  [36]. Mancini et al. [37] has demonstrated that Slug 
overexpression contributes to apoptosis resistance in leukemic progenitors. Manuela Mancini reported 
that Slug overexpression was involved in prolonged survival and imatinib(IM)resistance of Chronic 
myelogenous leukemia(CML) progenitors [37]. In this report, we demonstrated for the first time that 
Slug silencing could efficiently promote apoptosis in cholangiocarcinoma cells. Annexin-V/PI and 
TUNEL staining revealed that apoptotic cell death was abundant in cells with slug repression, but 
almost completely absent in cells transfected with mock-siRNA. These data demonstrate that the Slug 
silencing gene facilitates apoptosis.   
Slug, a highly conserved zinc finger transcriptional repressor, has been reported to antagonize 
apoptosis of hematopoietic progenitor cells by repressing PUMA transactivation [18]. In another study, 
it was demonstrated that suppression of the Slug gene facilitates apoptosis of fibroblast-like 
synoviocytes (FLS) by increasing PUMA transactivation [38].   
Our current findings show that when Slug was knocked down in the QBC939 cells, the PUMA and 
E-cadherin proteins were upregulated in the cells with the Slug supression. When caspase-3, a 
downstream gene induced by upregulation of PUMA, was blocked, the cell apoptosis caused by Slug 
silencing was reduced. These data demonstrate that Slug silencing facilitates apoptosis by PUMA 
upregulation, and not by E-cadherin upregulation.   
Recent studies have demonstrated that Slug silencing increases sensitivity to apoptosis induced by 
cisplatin, fotemustine, imatinib mesylate, etoposide, or doxorubicin [39,40]. Our study demonstrated Int. J. Mol. Sci. 2011, 12                 
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that Slug silencing markedly enhances cisplatin-induced apoptosis in cholangiocarcinoma cells in vivo 
and in vitro, and that Slug overexpression could contribute to impaired apoptosis (data not shown). 
The mechanism by which Slug silencing induced an increase in cisplatin-induced apoptosis involves 
the upregulation of PUMA; moreover, Slug suppression increases the capacity of cisplatin to block the 
cell cycle and induce cell death and such a phenomenon is also accompanied by the upregulation 
of PUMA.   
Previous studies have demonstrated that cisplatin-induced apoptosis in human bladder cancer cells 
and renal tubular cells was dependant upon PUMA [41,42]. However, Carly St has reported that 
cisplatin is a MAPK pathway dependent inducer of ATF3, whose expression influences cisplatin’s 
cytotoxic effects [43]. The mechanisms underlying the proapoptotic effect of the chemotherapeutic 
agent, cisplatin, are largely undefined. In the present study, we found that cisplatin caused significant 
induction of apoptosis of human cholangiocarcinoma cells in a time and concentration dependent 
manner and that this was associated with arrest of the cell cycle in G0-G1. We also found that cisplatin 
cytotoxicity is associated with PUMA induction, and when PUMA was suppressed the apoptosis 
induced by cisplatin was blocked. This suggests that an apoptosis-inducing mechanism triggered by 
cisplatin operates via PUMA in the cholangiocarcinoma cells. Another study, however, has found that 
PUMA induction by chemotherapeutic agents is abrogated in most human non-small-cell 
carcinoma(HNSCC)cell lines, and that cisplatin does not induce any increase in PUMA   
expression [44].   
To investigate whether the combination of Slug knockdown and cisplatin treatment can 
synergistically inhibit tumor growth and increase cholangiocarcinoma cell sensitivity to cisplatin, we 
used a well-established Xenograft tumor model in severe combined immunodeficient mice. Slug 
silencing or cisplatin alone inhibited Xenograft tumor growth, and the effects of both did reach 
statistical significance. This result is in contrast with the findings of the in vitro assays. When 
Slug-silenced cells were treated with cisplatin, significant growth suppression and apoptosis was 
demonstrated.  
Our results suggest that this combination of cisplatin and Slug suppression may be useful for 
chemoprevention and/or therapy of cholangiocarcinoma and possibly other types of cancer. Indeed, in 
recent unpublished studies we found that this combination exerts a synergistic inhibition of the growth 
of cholangiocarcinoma cells. These findings suggest the combination of cisplatin with Slug 
suppression might be an effective regimen for the chemoprevention and/or chemotherapy of various 
types of human malignancies. 
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